AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Jul 28, 2021

Advances in managing male genital tumors

Don't miss this Summer School on-demand content, available at your convenience.


Philippe E. Spiess, MD, MS, FRCS(C), FACS
Philippe E. Spiess, MD, MS, FRCS(C), FACS

Penile cancer is rare. However, certain factors can increase a man’s risk, including the absence of childhood circumcision, phimosis, chronic inflammation, poor penile hygiene, smoking, immunosuppression and infection with human papillomavirus (HPV).

Chemotherapy is still considered the mainstay for treating advanced penile cancer. Because of its toxic effects, poor response and nondurable outcome, thought leaders from around the globe are sharing best practices and recommendations during the AUA2021 on-demand session, “Updates in the Management of Penile Cancer: A Case-Based Approach.” The panel discussion led by Philippe E. Spiess, MD, MS, FRCS(C), FACS, was part of the AUA Summer School Series and evaluates important clinical considerations, the latest scientific literature and effective multimodal treatment approaches. Dr. Spiess is assistant chief of surgical services at Moffitt Cancer Center in Tampa.

“Annual updates on evidence-based guidelines from the National Comprehensive Cancer Network (NCCN) and European Association of Urology (EAU), for example, offer disease management guidance from early to advanced stage disease,” Dr. Spiess said. “This includes changes in staging based on pathology, chemotherapy and determining which patients are right for specific treatments based on staging.”

Recent NCCN and EAU updates have placed more focus on the local extent of the penile tumor. These updates are driving today’s treatment strategies, Dr. Spiess said. Advances in the understanding of male genital tumors (penile, scrotal and urethral), minimally invasive surgical approaches to the inguinal lymph nodes and multidisciplinary care to locally advanced disease are key considerations in patient care.

Other considerations are patterns of recurrence following inguinal lymph node dissection and the importance of optimizing surveillance strategies, Dr. Spiess said. Recent evidence suggests that patients diagnosed with penile squamous cell carcinoma have the greatest curative potential when inguinal lymphadenectomy is performed early. Most recurrences will occur within the first two to three years post-resection, but patients often need to be followed for more than five years to ensure that risk of recurrence is negligible.

“Minimally invasive surgery can be a very suitable treatment for early inguinal nodal disease, particularly with robotics, but in the setting of bulky or higher volume disease, a meticulous and complete quality surgery using an open approach by an experienced surgeon cannot be overemphasized to ensure patients have the best outcomes,” Dr. Spiess said. “You best get it right the first time around.”

Multimodal therapies continue to make a difference in some cases, according to Dr. Spiess. For example, early and emerging data show that, in a subset of patients with likely unresectable disease, radiation to shrink the tumor before surgery may have clinical merit, most notably in HPV-positive penile cancer compared to HPV-negative tumors. Prior work by Dr. Speiss’ group has shown increasing radiosensitivity of the HPV-positive tumors reflecting what is seen in head and neck oncology for squamous cell carcinomas.

Finally, the on-demand session discusses the importance of identifying the clinical and pathologic features that favor the use of adjuvant therapy following surgical management of penile cancer. Citing a National Cancer Institute study, Dr. Spiess said the role of adjuvant therapy in treating penile cancer is limited, particularly if it is diagnosed with adverse pathological features such as extranodal extension.

“In such cases, there is a higher risk of progression, and clinicians should look at chemotherapy, radiotherapy, clinical trials and novel therapies,” he said.

Although penile cancer is rare, Dr. Spiess underscored the profound impact that localized and advanced penile cancer treatment has on a patient’s quality of life, both physically and psychosexually. 

Visit AUA2021 Daily News Online for more articles.

Register to view on-demand content today! This feature is available for registrants who purchase platinum or silver packages.

https://www.aua2021.org/register

Interesting Stories
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
More Content
Getty Images 1208851295
AUA2022
Save the date
Jan 31, 2022
Aua Wrap 04
AUA2021
AUA2021 On Demand: see what’s streaming
Sep 22, 2021
Aua Wrap 03
AUA2021
Satellite symposia bring expert insights
Sep 22, 2021
Aua Wrap 01
AUA2021
Education and training for young urologists
Sep 22, 2021
Getty Images 1199215126
AUA2021
Claim your CME
Sep 22, 2021
Aua Wrap 05
AUA2021
Read all about it
Sep 22, 2021
Aua Tv
AUA2021
Must-see TV
Sep 22, 2021
Getty Images 185224486
AUA2021
AUA2021: By the numbers
Sep 15, 2021
Toni K. Choueiri, MD
AUA2021
Late-breaking science
Sep 15, 2021
Ian M. Thompson Jr., MD
AUA2021
Award winners
Sep 15, 2021
Tips And Tricks
AUA2021
Guideline updates
Sep 15, 2021
Ai
AUA2021
New technology
Sep 15, 2021
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.